Illustrative. Possible ways AlphaGenome can help.
What kinds of breakthroughs has AlphaGenome enabled?
AlphaGenome is still pretty new. We launched it in June 2025, and we just introduced AlphaGenome Atlas in September this year. But researchers are already using it to advance science.
Gareth Hawkes, a Medical Research Council fellow at the University of Exeter, used AlphaGenome Atlas to narrow down a list of 1 billion genetic variants. By focusing on the most impactful 1%, he identified 19 variant groups linked to body mass index to prioritize in his research.
And Laura Covill, a Broad Institute research fellow, used the AVI score to prioritize genetic variants in their research of unsolved rare diseases. AlphaGenome Atlas identified a critical variant in a gene linked to neurodevelopmental disorders, providing crucial supporting evidence that drove their subsequent research, including solving the case.
What are you hoping to do next?
We just launched our latest model, AlphaGenome 2, which tackles one of the key limitations of AlphaGenome: cell type specificity. While AlphaGenome is state-of-the-art, it was trained mostly on data from whole tissues or cell lines. We know that individual cell types in those tissues have a very specific role and can malfunction in disease. AlphaGenome 2 moves beyond tissue-level averages to predict how genetic variants disrupt these individual cell types, helping researchers pinpoint the cellular drivers of disease.
We’re also actively researching better ways to measure how confident our model is in its predictions so researchers know how much to trust each result. From early analyses, we see that variants with strongly predicted effects are quite good and achieve high levels of accuracy. As always, anyone using AlphaGenome should interpret its predictions with other sources of information.
What’s the ultimate goal of your work in biology?
In the short term, we’d like to use AI to better understand the grammar of the genome and accurately predict the effects of mutations. In the long term, we’d like to build on this foundation towards a fully functioning digital simulation of a human cell.
This will allow researchers to computationally model disease mechanisms, understand rare genetic conditions, and test candidate therapies.




